Goldman Sachs is out with a research note this morning, where it suggests that traders buy calendar spreads on Aruba Networks UTHR ahead of upcoming positive Phase 3 data.
Goldman Sachs Biotechnology analyst, Terence Flynn, rates UTHR shares Buy and sees 19% upside to his 12-month price target of $82. He rates UTHR a M&A probability of 1 (strong, 30% - 50% probability in one year) once results from Phase 3 data on their upcoming Pulmonary Arterial Hypertension (PAH) are released this year.
Goldman suggests buying the August $75.00 call and selling the January 2012 $90.00 call for a net debit of $1.45
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the medical needs of patients with chronic diseases.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.